Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

BACKGROUND: SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we report results of immunogenicity, safety, and reactogenicity of SOBERANA 02 in a two- or three-dose heterologous scheme in adults. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Toledo-Romani, María Eugenia, García-Carmenate, Mayra, Verdecia-Sánchez, Leslyhana, Pérez-Rodríguez, Suzel, Rodriguez-González, Meybis, Valenzuela-Silva, Carmen, Paredes-Moreno, Beatriz, Sanchez-Ramirez, Belinda, González-Mugica, Raúl, Hernández-Garcia, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, Pérez-Guevara, María Teresa, Enriquez-Puertas, Juliet, Noa-Romero, Enrique, Palenzuela-Diaz, Ariel, Baro-Roman, Gerardo, Mendoza-Hernández, Ivis, Muñoz, Yaima, Gómez-Maceo, Yanet, Santos-Vega, Bertha Leysi, Fernandez-Castillo, Sonsire, Climent-Ruiz, Yanet, Rodríguez-Noda, Laura, Santana-Mederos, Darielys, García-Vega, Yanelda, Chen, Guang-Wu, Doroud, Delaram, Biglari, Alireza, Boggiano-Ayo, Tammy, Valdés-Balbín, Yury, Rivera, Daniel G., García-Rivera, Dagmar, Vérez-Bencomo, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Clinical Advances
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359498/
https://www.ncbi.nlm.nih.gov/pubmed/35998623
http://dx.doi.org/10.1016/j.medj.2022.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359498/
https://www.ncbi.nlm.nih.gov/pubmed/35998623
http://dx.doi.org/10.1016/j.medj.2022.08.001

Ejemplares similares